To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.
This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19 and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in mild to moderate symptomatic patients who consent to randomization following a new diagnosis in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test remained positive..
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
180
Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
0.9% normal saline
Zinc Sulphate 20mg 3 times a day
Ali Clinic
Lahore, MA, Pakistan
RECRUITINGShaikh Zayed Hospital
Lahore, Punjab Province, Pakistan
RECRUITINGqRT-PCR
time needed to turn positive COVID-19 PCR to negative
Time frame: 14 days
Time taken for alleviation of symptoms
time needed to turn off symptoms
Time frame: upto 14 days
Severity of symptoms
time needed of symptom serverity
Time frame: upto 14 days
Severity of symptoms
time needed to make patients clinically better
Time frame: 14 days
Morality
death rate
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo empty capsule
0.2mg/kg/day